Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

Ian F. Faneyte(The Netherlands Cancer Institute), Marc J. van de Vijver(The Netherlands Cancer Institute), P L Remijnse(The Netherlands Cancer Institute), J.L. Peterse(The Netherlands Cancer Institute), Jolanda Schrama(Amsterdam Public Health), Sjoerd Rodenhuis(The Netherlands Cancer Institute)
British Journal of Cancer
February 1, 2003
10.1038/sj.bjc.6600749
Cited by 316

Related Papers

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The landscape of cancer genes and mutational processes in breast cancer
|Nature|2012|1.7k
K-<i>ras</i>Oncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung
|New England Journal of Medicine|1990|811
Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy
|JNCI Journal of the National Cancer Institute|1998|768
Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial
|Journal of Clinical Oncology|2015|655